Affordable Access

Access to the full text

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

Authors
  • Striefler, Jana Käthe1
  • Brandes, Franziska1
  • Baur, Alexander2
  • Pfitzner, Berit Maria3
  • Kaul, David2
  • Rau, Daniel4
  • Dörr, Anne1
  • Schmiester, Maren1
  • Koulaxouzidis, Georgios5
  • Bullinger, Lars1, 6
  • Märdian, Sven4
  • Flörcken, Anne1
  • 1 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, 13353, Germany , Berlin (Germany)
  • 2 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Germany , Berlin (Germany)
  • 3 DRK Kliniken Berlin Köpenick, Institut für Pathologie, Berlin, Germany , Berlin (Germany)
  • 4 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Centre for Musculoskeletal Surgery, Campus Virchow-Klinikum, Berlin, Germany , Berlin (Germany)
  • 5 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Plastic and Reconstructive Surgery, Campus Virchow-Klinikum, Berlin, Germany , Berlin (Germany)
  • 6 German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany , Heidelberg (Germany)
Type
Published Article
Journal
BMC Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 29, 2020
Volume
20
Issue
1
Identifiers
DOI: 10.1186/s12885-020-6551-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundThe antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context.MethodsHere, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019.ResultsMedian progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6–16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD.ConclusionsThis single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS.

Report this publication

Statistics

Seen <100 times